

SYSTEMATIC REVIEW

IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review

Olfat Ahmad^{1,2,3,4,5} , Tahani Ahmad^{6,7} and Stefan M. Pfister^{1,2,8}

1 Division of Pediatric Neurooncology, Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany

2 Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany

3 Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany

4 University of Oxford, Oxford, UK

5 King Hussein Cancer Center (KHCC), Amman, Jordan

6 Department of Pediatric Neuroradiology, IWK Health Center, Halifax, Canada

7 Dalhousie University, Halifax, Canada

8 Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany

Keywords

IDH-mutant glioma; immunogenicity; PMMRDIA

Correspondence

S. M. Pfister, Division of Pediatric Neurooncology, Hopp Children's Cancer Center (KiTZ), Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany
 Fax: +49 6221 42-4639
 Tel: +49 6221 42-4618
 E-mail: s.pfister@kitz-heidelberg.de

(Received 27 September 2023, revised 28 December 2023, accepted 22 January 2024, available online 9 February 2024)

doi:10.1002/1878-0261.13598

In 2021, Suwala *et al.* described Primary Mismatch Repair Deficient IDH-mutant Astrocytoma (PMMRDIA) as a distinct group of gliomas. In unsupervised clustering, PMMRDIA forms distinct cluster, separate from other IDH-mutant gliomas, including IDH-mutant gliomas with secondary mismatch repair (MMR) deficiency. In the published cohort, three patients received treatment with an immune checkpoint blocker (ICB), yet none exhibited a response, which aligns with existing knowledge about the decreased immunogenicity of IDH-mutant gliomas in comparison to IDH-wildtype. In the case of PMMRDIA, the inherent resistance to the standard-of-care temozolomide caused by MMR deficiency is an additional challenge. It is known that a gain-of-function mutation of IDH1/2 genes produces the oncometabolite R-2-hydroxyglutarate (R-2-HG), which increases DNA and histone methylation contributing to the characteristic glioma-associated CpG island methylator phenotype (G-CIMP). While other factors could be involved in remodeling the tumor microenvironment (TME) of IDH-mutant gliomas, this systematic review emphasizes the role of R-2-HG and the subsequent G-CIMP in immune suppression. This highlights a potential actionable pathway to enhance the response of ICB, which might be relevant for addressing the unmet therapeutic challenge of PMMRDIA.

Abbreviations

5-mC, 5-methylcytosine; A, adenine; AML, acute myeloid leukemia; C, cytosine; CGGA, Chinese Glioma Genome Atlas; CMMRD, constitutional mismatch repair deficiency; CNS, central nervous system; CTA, cancer testis antigens; DCs, dendritic cells; DKFZ, German Cancer Research Centre; DNMT1, DNA methyltransferase 1; FACS, fluorescence-activated cell sorting; FDG, 18F-fluorodeoxyglucose; G, guanine; GBM, glioblastoma; G-CIMP, glioma-associated CpG island methylator phenotype; GO, gene ontology; HLA, human leukocyte antigen; HUGO, Human Genome Organization; ICB, immune checkpoint blocker; IHC, immunohistochemical; IRRDC, International Replication Repair Deficiency Consortium; LGG, low-grade glioma; MAGE, melanoma-associated antigens; MDS, myelodysplastic syndrome; MGMT, O-6-methylguanine-DNA methyltransferase; MMR, mismatch repair; N7-mG, N7-methylated G; NFAT, nuclear factor of activated T cells; NKG2DL, NK group 2D ligand; O6-mG, O6-methylated G; PBMCs, peripheral blood mononuclear cells; PMMRDIA, Primary Mismatch Repair Deficient IDH-mutant Astrocytoma; PMNs, polymorphonuclear leukocytes; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PROSPERO, Prospective Register of Systematic Reviews; qPCR, quantitative PCR; R-2-HG, R-2-hydroxyglutarate; RNA-seq, RNA-sequencing; ROS, reactive oxygen species; RT, radiotherapy; T, thymine; TAMs, tumor-associated microglia/macrophages; TCGA, The Cancer Genome Atlas; TCR, T cell receptor; TMB, tumor mutational burden; TME, tumor microenvironment; TMZ, temozolomide; t-SNE, t-distributed stochastic neighbor embedding; U, Uracil; WHO, World Health Organization.

1. Introduction

1.1. Placement of *IDH* mutation in the glioma classification and placement of the PMMRDIA group within IDH-mutant gliomas

After being first recognized in a single case of colorectal carcinoma in 2007 [1], *IDH* mutations have been identified in various types of human malignancies including – among others – acute myeloid leukemia (AML), intrahepatic cholangiocarcinoma, chondrosarcoma, and thyroid carcinoma [2–5]. In glioma, the diagnostic and prognostic significance of *IDH* mutation was first identified in 2008 [6,7]. Since 2016, the World Health Organization (WHO) has introduced molecular markers in its classification of central nervous system (CNS) tumors, allowing IDH-mutant gliomas to be defined by their molecular features resulting in a more accurate diagnosis [8,9]. In comparison to IDH-wildtype gliomas of the same grade, IDH-mutant gliomas are associated with a rather favorable prognosis [10], and they occur in ~ 80% of WHO grade II/III gliomas [11]. While only ~ 10% of glioblastoma (GBM) of WHO grade IV (current nomenclature is WHO grade IV diffuse glioma) are IDH-mutant [12], they are particularly enriched in secondary diffuse glioma grade IV (73% vs. 3.7%), suggesting malignant transformation of a lower-grade primary IDH-mutant gliomas [11]. It is thought that more than half of the cases of recurrent IDH-mutant gliomas develop secondary mismatch repair (MMR) deficiency, as a resistance mechanism to temozolomide (TMZ) [12], which is the most commonly used chemotherapeutic agent in treatment protocols of glioma (together with radiotherapy, following surgery) [13]. These recurrent IDH-mutant gliomas with secondary MMR deficiency comprise the first of the two described entities of diffuse gliomas with co-occurrence of *IDH* mutation, MMR deficiency, and hypermutation. The second being the recently defined Primary Mismatch Repair Deficient IDH-mutant Astrocytoma (PMMRDIA) [14]. Both of these entities share an additional characteristic of TMZ resistance, which is inherent to primary mismatch repair deficient gliomas, hereafter referred to as dMMR gliomas [15]. In restricted t-distributed stochastic neighbor embedding analyses conducted by Suwala *et al.* [14], primary and secondary MMR deficient IDH-mutant astrocytomas were completely separated, hence, the definition of the distinct new group of PMMRDIA. Notably, in contrast to other IDH-mutant gliomas, where O-6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation is a common feature in majority of the cases,

PMMRDIA shows the highest frequency of unmethylated *MGMT* promotor [14]. Other than these two entities, the WHO classification of CNS tumors 2021 recognizes the following types of IDH-mutant gliomas: diffuse astrocytoma (WHO grade II), anaplastic astrocytoma (WHO grade III), oligodendroglioma 1p/19q-codeleted (WHO grade II), and anaplastic oligodendroglioma 1p/19q-codeleted (WHO grade III) [9]. Needless to mention that similar to other types of astrocytoma, PMMRDIA is characterized by intact 1p/19q and high-frequency *ATRX* inactivation [14].

1.2. MMR deficiency, *MGMT* promotor hypermethylation, and TMZ resistance

TMZ is an alkylating agent, that preferentially methylates DNA at O₃ position of adenine (A), together with the N7 and O6 positions of guanine (G). Although N7-methylated G (N7-mG) is the major DNA adduct induced by TMZ, the cytotoxicity and mutagenicity are primarily attributed to the O6-methylated G (O6-mG) lesion [16]. O6-mG lesions are directly repaired by MGMT [12]. Instead of pairing with cytosine (C), O6-mG pairs with thymine (T) creating a mismatch that is recognized by DNA MMR machinery, which repairs the daughter strand but leaves behind the O6-mG in the template strand for MGMT repair. A single MGMT molecule can only repair one alkyl adduct, and therefore, the repair of O6-mG adducts is dependent on the number of MGMT molecules per cell and on the rate of MGMT regeneration [12]. The unrepaired O6-mG leads to repeated attempts by the MMR pathway in a process called futile cycling, that results in replication-associated DNA double-strand breaks, which culminates in cell death [17]. Thus, TMZ cytotoxicity depends on an intact MMR pathway and low levels of MGMT, as is the case in MGMT promotor methylation (Fig. 1). This mechanism also explains the inherent resistance of dMMR tumors to TMZ [15]. Hence, Suwala *et al.* [14] did not show a difference in patients' outcomes for PMMRDIA with or without MGMT promotor methylation.

TMZ, similar to other alkylating agents, induces a mutagenic effect on the genome through DNA methylation and subsequent mismatches. In the model proposed by Choi *et al.* [12], TMZ resistance, which is marked by a hypermutator signature, occurs due to a TMZ-induced mutation at a key amino acid of an MMR gene. Indeed, pre-existing heterozygous deletions encompassing *MGMT*, or an MMR gene had been observed in some gliomas which later developed hypermutated recurrence, highlighting the survival advantage of these two events [12].




Fig. 1. The mechanism of action of temozolomide. MGMT, O-6-methylguanine-DNA methyltransferase; MMR, mismatch repair; N7-mG, N7-methylguanine; O3-mA, O3-methyladenine; O6-mG, O6-methylguanine. The figure illustrates the dependency of TMZ on MMR machinery, together with low levels of MGMT.

1.3. PMMRDIA: Diagnostic and therapeutic challenge

Since *IDH* enrichment has not been previously described in dMMR gliomas, the diagnosis of PMMRDIA could be overlooked as an IDH-mutant glioma based on IDH immunohistochemical (IHC) staining alone, unless a suspicion of dMMR existed, especially in the context of treatment-naïve glioma. Notably, the disparate global distribution of the autosomal-recessive-inherited constitutional mismatch repair deficiency (CMMRD) syndrome, which correlates with a large proportion of PMMRDIA cases, is concentrated in countries of high consanguinity such as the Middle East [18]. In cases of IDH-mutant gliomas with intact 1p/19q or loss of *ATRX* as a surrogate in a child, adolescent, or young adult, a heightened level of suspicion is warranted, particularly if the histology exhibits high-grade features. This recommendation is in accordance with Suwala *et al.* [14]. Not only in the typical setup of high CMMRD suspicion score, such as when there is a suggestive family history of Lynch syndrome spectrum

tumors, or clinical features of neurofibromatosis 1 [19]. Indeed, newer versions of the molecular neuropathology methylation classifier developed by the German Cancer Research Centre (DKFZ), Heidelberg [20], will include PMMRDIA, which will aid the accurate diagnosis of this tumor group.

In the last decade, MMR deficiency has gained recognition as an indication for immune checkpoint blockers (ICBs). This marked a significant milestone with the first tissue-agnostic cancer-drug approval by the US Food and Drug Administration, following the publication of Le *et al.* 2015 [21]. Despite the fact that hypermutant gliomas are less responsive to ICB, due to their relative immunosuppressive microenvironment and the subclonal nature of the vast majority of mutations in MMR-deficient tumors [22], several retrospective reports together with a recently published clinical trial by the International Replication Repair Deficiency Consortium (IRRDC) [23], have shown durable responses and prolonged survival of pediatric gliomas with high mutational burden and MMR deficiency [22]. Nevertheless, in the published cohort of Suwala *et al.* [14], none of the

three patients who received ICB treatment during the course of the disease showed a notable response, attributed to *IDH* mutation or probably to small number of studied patients in the published cohort.

1.4. Understanding the molecular effects of an *IDH* event on a glioma

In humans, the IDH enzyme family includes three isoforms: IDH1, IDH2, and IDH3 [4]. All three forms are essential for several metabolic processes, such as the Krebs cycle, glutamine metabolism, lipogenesis, and redox regulation [24]. *IDH1/2* mutations that are associated with cancer tend to localize to the arginine (R) residue that is crucial for the recognition of isocitrate (R132 for *IDH1*, R140 or R172 for *IDH2*), with a vast majority of *IDH1* R132H events [7]. On the other hand, none of the three IDH3-coding genes (*IDH3A*, *IDH3B*, and *IDH3G*) have been identified as significantly mutated genes in human cancers [4]. IDH enzymes normally convert isocitrate to α -ketoglutarate (α -KG) in the tricarboxylic acid (TCA) cycle. However, in IDH-mutant gliomas, the mutated enzyme acquires a neomorphic function, converting α -KG to R-2-hydroxyglutarate (R-2-HG) [25–27]. It is understood that R-2-HG interferes with the activity of multiple α -KG-dependent hydroxylases, exerting metabolic and epigenetic reprogramming of IDH-mutant cancer cells, in addition to inducing paracrine effects on the TME [28].

1.4.1. Metabolic effect of intracellular R-2-HG accumulation

The accumulation of R-2-HG disrupts various cellular metabolic pathways, contributing to tumorigenesis and malignant progression. One crucial aspect is the impact on cellular redox homeostasis. The conversion of α -KG to R-2-HG consumes NADPH, a critical reducing agent involved in preventing oxidative stress. The reduced NADPH availability compromises the cell's ability to combat reactive oxygen species (ROS) and maintain redox balance, leading to increased oxidative stress and potential DNA damage, which further drives tumor development. Moreover, the alteration in the TCA cycle caused by *IDH* mutation has implications in energy metabolism. IDH-mutant gliomas display decreased flux through the TCA cycle, leading to reduced ATP production via oxidative phosphorylation [29]. To compensate for the energy deficit, these tumors often rely on alternative metabolic pathways, such as aerobic glycolysis (the Warburg effect), to generate ATP and support their rapid proliferation. This shift in energy metabolism contributes to the characteristic metabolic phenotype

observed in gliomas and is associated with increased glucose uptake, commonly observed in positron emission tomography imaging using 18F-fluorodeoxyglucose (FDG) [30]. Furthermore, IDH-mutant gliomas exhibit altered lipid metabolism. Studies have shown that *IDH* mutations can influence the expression and activity of lipid biosynthetic enzymes, leading to increased lipogenesis and lipid accumulation in tumor cells. Lipids serve as a crucial source of energy and building blocks for cell membranes, and dysregulated lipid metabolism in IDH-mutant gliomas affects their growth and survival. Altogether, these metabolic changes create a unique metabolic profile in IDH-mutant gliomas, making them distinct from other glioma subtypes [31]. This lays the groundwork for the development and utilization of several targeted IDH1/2 inhibitors in the treatment of IDH-mutant glioma and other IDH-mutant tumors [32].

1.4.2. IDH-induced epigenetic reprogramming of tumor cells

Epigenetic dysregulation exerted by an *IDH* event is a fundamental characteristic of gliomagenesis, in addition to the described metabolic effects. Among enzymes inhibited by R-2-HG, are demethylases, namely, TET family of 5-methylcytosine hydroxylases [33] and lysine demethylases [34], leading to widespread alterations in DNA and histone methylation patterns, respectively. The aberrant DNA hypermethylation observed in IDH-mutant gliomas is particularly evident at CpG islands, repressing critical tumor suppressor genes involved in cell cycle regulation, DNA repair, and apoptosis. This epigenetic silencing contributes to uncontrolled cell proliferation and tumor growth, which is the hallmark of IDH-mutant gliomas, alternatively called as the glioma-associated CpG island methylator phenotype (G-CIMP) [4,35]. Additionally, IDH mutations impact histone methylation, which alters chromatin structure and gene regulation, affecting chromatin accessibility and transcriptional activity. These changes can enhance the expression of oncogenes or suppress the tumor suppressor genes, thereby, driving glioma development. Furthermore, the epigenetic effect of *IDH* mutation may influence cellular differentiation processes. Additionally, R-2-HG can interfere with enzymes involved in cellular differentiation pathways, promoting a dedifferentiated state in glioma cells. This loss of normal cellular identity may contribute to the glioma's malignant potential and aggressive behavior [36]. The effectiveness of inhibiting methylation in IDH-mutated glioma cells was supported by Turcan *et al.* [37], which demonstrated that decitabine, an inhibitor of DNA methyltransferase 1

(DNMT1) suppresses the proliferation of IDH-mutant glioma cells both *in vitro* and *in vivo*. Likewise, Boro-dovsky *et al.* [38] observed that 5-azacytidine, a cytidine analog that interferes with the activity of DNA methyltransferase, led to the regression of a patient-derived IDH-mutant glioma xenograft.

1.4.3. Paracrine effect of 2-HG on the TME

Elevated levels of R-2-HG have been detected both inside tumor cells and in the serum of several types of IDH-mutant tumors [25–27]. This finding helps to elucidate how the accumulation of R-2-HG may lead to a survival advantage for glioma cells, despite potentially disrupting multiple metabolic pathways that compromise cellular fitness. It became evident that the export of excess intracellular R-2-HG into the tumor microenvironment (TME) and bodily fluids serves as a protective mechanism in tumor cells [28]. Subsequent import of R-2-HG to T lymphocytes in a paracrine fashion was first described in IDH-mutant gliomas by Bunse *et al.* in 2018 [28], who also reported that the sodium transporter aids the import of R-2-HG. Evidence collected subsequently from Bunse *et al.* and other groups suggest that R-2-HG exerts its intracellular effects on T cells through metabolic rather than epigenetic reprogramming [28,39,40]. Probably, the exported R-2-HG gets imported to subclones of IDH-mutant glioma lacking the *IDH* mutation as well, which could further explain the dominating effect of an *IDH* mutation on dictating the characteristics of IDH-mutant gliomas. This latter aspect still needs to be examined.

1.5. Mechanisms of immune modulation in IDH-mutant glioma

In addition to oncogenesis, an *IDH* mutation, through the three molecular mechanisms described above, has the potential to influence various aspects of the immune activation cycle, at two main levels of control. The first is downregulation of genes involved in immune activation in cancer cell itself, and the second is through the direct paracrine effect on TME. Downregulation of immune-related genes is achieved either by a direct metabolic inhibitory effect of R-2-HG or through epigenetic reprogramming by hypermethylation of promoters of immune-related genes. Similar to the results by Suwala *et al.*, lack of response of MMR pIDH-mutant glioma to ICB due to an immunosuppressive TME has been studied in detail [11,28,41–53].

This systematic review provides a comprehensive overview of these mechanisms through which acquiring an *IDH* mutation and subsequent generalized DNA

promoter methylation, affect various aspects of immune activation cycle in IDH-mutant gliomas. The aim of this review is to highlight this pathway as a potential actionable therapeutic target that could be considered for testing in combination with an ICB to enhance the immunological response. Such combination therapy could be promising for PMMRDIA patients, thereby, addressing the unmet therapeutic challenge of dual resistance to ICB and TMZ.

2. Methodology

2.1. Design and registration

The study design was set as a systematic review. The protocol has been registered in the International Prospective Register of Systematic Reviews (PROSPERO), under the registration ID number CRD42023461700. The review was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [54]. By adhering to these guidelines, we aimed to enhance the clarity and completeness of our review and facilitate its reproducibility.

2.2. Search strategy and software used

Medline (ovid) and Embase Databases were searched for publications published until 5th July 2023. The search strategy was based on the following three components: *IDH* mutation, tumor immunogenicity (including tumor mutational burden), and gliomas. A combination of the Boolean operators (and, or) was employed to combine the search terms effectively (Fig. 2). Two collaborators (O.A. and T.A.) carried out title and abstract screening independently to prevent screening bias, utilizing the RAYYAN software [55]. Subsequently, both collaborators resolved any disagreement through discussion and consensus. The full texts of the articles identified as potentially relevant, during the abstract and title screening phase, were obtained for further evaluation in the subsequent full-text screening stage by O.A.

While RAYYAN software was used to automate the illustration of the PRISMA statement, PowerPoint was employed in creating the final version of Fig. 3, together with Fig. 2. The graphical abstract and Fig. 1 were created using INKSCAPE software.

2.3. Inclusion criteria

The following inclusion criteria were established: only original research papers in English language were considered. No specific time frame for the year of publication was defined. Included papers had to be original




Fig. 2. Search strategy. The figure illustrates the three search components, together with the used Boolean operators.

research studies specifically investigating the impact of *IDH* mutation on the immunogenicity of glioma. To ensure the availability of comprehensive information, only papers that had the full manuscript available online were included. Only papers addressing a specific aspect of the immunity affected by *IDH* mutation were included (i.e., papers reporting an immunosuppressive TME of *IDH*-mutant glioma without pointing out the specifically affected component of the immune cycle were excluded as mentioned in Section 2.4). Finally, as could be noticed from the search strategy, the systematic review included manuscripts reporting the effect of *IDH* mutation on the tumor mutational burden (TMB), even without directly addressing the effect on immunogenicity, because the effect of TMB on tumor immunogenicity is well understood.

2.4. Exclusion criteria

Several exclusion criteria were applied to maintain the focus and rigor of the systematic review. Firstly, studies that did not address the effect of *IDH* mutation on the immunogenicity of gliomas were excluded. For instance, studies where search terms only appeared together in the abstract but had a different primary focus were omitted. Likewise, manuscripts that specifically focused on the influence of another mutation co-occurring in *IDH*-mutant gliomas, but not *IDH* mutation itself, were also excluded from this review. Secondly, review papers were excluded from consideration, as they do not present original research findings. Thirdly, conference abstracts were also excluded as the full manuscript was not available for critical appraisal of the methods and findings. Finally, manuscripts not defining any clear aspect of the immune cycle affected by *IDH* mutation were also excluded from data extraction; however, most of them were cited in the introduction section, as they provided supporting observations

that this systematic review aims to elucidate. Some studies were excluded for more than one reason.

2.5. Data extraction

Data extraction was conducted by a single author (O.A.), who meticulously reviewed the included studies to extract relevant information. Throughout the data extraction process, special attention was given to the molecular mechanisms of how *IDH* mutation induces the studied effect on the immunogenicity of gliomas. As downregulation of immune-related genes within the tumor cell or affected immune cells, is the dominant mechanism of action, a special focus was placed on the role of methylation in silenced genes. In addition, considering that the aim of this systematic review is to highlight the potential therapeutic impact of targeting *IDH* mutation or methylation in combination with an ICB, manuscripts that employed an *IDH* inhibitor or a methylation inhibitor within their design were identified. Finally, critical appraisal of the methods followed in the manuscripts was assessed. This assessment aimed to determine whether the observed effects of *IDH* mutation on the TME were merely associated or if they were further validated by the investigators through *in vitro* or *in vivo* studies, demonstrating a causal relationship. Table 1 provides a summary of the studies used for data extraction, along with the aforementioned key points, and manuscripts' citations, which serve as an indicator of their significance. More details regarding the characteristics of eligible studies are provided in Section 3.1.

3. Results

3.1. Eligible studies

During screening of the databases, 949 potentially relevant articles were identified. After removing duplicates,




Fig. 3. PRISMA statement. PRISMA, preferred reporting items for systematic reviews and meta-analyses. This diagram depicts the flow of studies through the systematic review process in accordance with the PRISMA guidelines. It outlines the identification, screening, eligibility, and inclusion/exclusion of studies at each stage.

584 articles qualified for analysis. On the basis of the available abstracts, 356 publications were rejected and 108 were accepted for comprehensive full-text analysis. These selected full texts were then carefully scrutinized according to the pre-defined inclusion and exclusion criteria. Eventually, 23 articles that elucidated the impact of *IDH* mutation on various aspects of immune activation were accepted for review, having met the eligibility criteria (Fig. 3). Four manuscripts addressed downregulation of antigen presentation in IDH-mutant gliomas, either by downregulation of MHC molecules of tumor cells in two manuscripts or lower TMB of IDH-mutant gliomas in three papers, with one of the latter being one of the formerly mentioned two manuscripts. In the realm of immune cells, three manuscripts addressed an inhibitory effect of *IDH* mutation on chemotaxis of immune cells to TME, one manuscript explored an immune escape mechanism from NK cells, two manuscripts explained the

inhibition of dendritic cells, three delved into functional inhibition of T cells, in addition to the manuscript highlighting decreased T cell chemotaxis; all impacting the innate immune responses. On the other hand, two manuscripts suggested increased phagocytic activity of macrophages. Noteworthy, eight manuscripts addressed downregulation of immune checkpoint expression on tumor cells of IDH-mutant glioma, with PDL-1 downregulation emphasized in five of them, providing a direct mechanism for ICB resistance, in addition to the immunosuppressive TME.

3.2. IDH-induced effect on antigen presentation

3.2.1. IDH-induced downregulation of MHC expression

In 2021, Lin *et al.* evaluated RNA-sequencing (RNA-seq), somatic mutation, and clinical data from 1052 low-grade glioma (LGG) from the cancer genome atlas (TCGA) and Chinese glioma genome atlas (CGGA),

Table 1. Summary of studies included for data extraction.

Mechanism	References	Citations up to July 2023	Downregulation of examined genes is attributed to methylation	Major limitations of the study	Studied effect modulated by a methylation inhibitor	Studied effect modulated by an IDH inhibitor
1 MHC	Lin <i>et al.</i> , 2021	21	–	No validation <i>in vivo</i> or <i>in vitro</i>	–	–
2 downregulation	Louto <i>et al.</i> , 2018	31	Yes	–	Yes	–
3 Lower TMB	Wang <i>et al.</i> , 2020	56	Not related	Association described, without explanation	–	–
4	Lin <i>et al.</i> , 2021	21	–	–	–	–
5 Chemotaxis	Suwala <i>et al.</i> , 2021	52	–	–	–	–
6	Kohanbash <i>et al.</i> , 2017	303	No	–	–	Yes
7	Amankulor <i>et al.</i> , 2017	310	–	–	–	–
	Ren <i>et al.</i> , 2019	46	–	Conflicting results between two examined datasets	–	–
8 T cell responses	Kohanbash <i>et al.</i> , 2017	303	No	–	–	Yes
9	Bunse <i>et al.</i> , 2018	344	No	–	–	Yes
10	Notarangelo <i>et al.</i> , 2022	41	No	–	–	–
11 NK Cell function	Afsari <i>et al.</i> , 2023	–	No	–	–	–
	Zhang <i>et al.</i> , 2016	132	Yes	Validation not specifically addressing the suggested effect	Yes	–
12 Dendritic cell function	Ugele <i>et al.</i> , 2019	15	–	Unclear definition of the studied effect	–	–
13	Friedrich's <i>et al.</i> , 2023	14	–	–	–	–
14 Macrophage function	Gowda <i>et al.</i> , 2018	31	–	–	–	–
15	Ma <i>et al.</i> , 2021	13	Yes	–	–	–
16 PDL-1 downregulation	Wang <i>et al.</i> , 2016	162	–	Association described, but no validation done and no explanation provided	–	–
17	Berghoff <i>et al.</i> , 2017	218	Yes	Explanation provided without validation	–	–
18	Mu <i>et al.</i> , 2018	68	Yes	<i>In-vitro</i> validation failed to maintain long lasting effect	–	–
19	Röver <i>et al.</i> , 2018	60	Yes	No comparison to IDH-wildtype	–	–
20	Kadiyala <i>et al.</i> , 2021	64	–	–	–	Yes
21 Modulation of other immune checkpoints	Röver <i>et al.</i> , 2018	60	Yes	No comparison to IDH-wildtype	–	–
22	Liu <i>et al.</i> , 2020	6	–	No validation done	–	–
23	Sørensen <i>et al.</i> , 2020	4	–	No validation done	–	–
	Zhang <i>et al.</i> , 2021	4	–	–	–	–

*Manuscripts appearing twice in the table.

and illustrated a gradual decrease in expression of several human leukocyte antigen (*HLA*) genes encoding the MHC class I proteins from the IDH-wildtype to IDH-mutant 1p/19q co-deleted (current WHO nomenclature is oligodendroglioma IDH-mutant and 1p/19q-codeleted), with IDH-mutant non-co-deleted (current WHO nomenclature is astrocytoma IDH-mutant) occupying an intermediate position in this expression pattern. Studied genes are *HLA-A*, *HLA-B*, *HLA-C*, *HLA-DMA*, *HLA-DMB*, *HLA-DOA*, *HLA-DOB*, *HLA-DPA1*, *HLA-DPB1*, *HLA-DPB2*, *HLA-DQA1*, *HLA-DQA2*, *HLA-DQB1*, *HLA-DRA*, *HLA-DRB1*, *HLA-DRB5*, *HLA-E*, *HLA-F*, *HLA-H*, *HLA-J*, and *HLA-L*. Methylation analysis was not performed for the included cohorts, and no validation was done to attribute the described effect to *IDH* mutation. Notably, there is a consistent pattern of differential TMB among the three described subtypes [56], as further described in paragraph 3.2.2. It could be argued that the findings of Lin *et al.* are partially supported by the findings previously published studies in 2018 by Luoto *et al.*, which analyzed RNA-seq and methylation data of 154 GBM (current nomenclature is WHO grade IV diffuse glioma) from TCGA, and reported lower expression and higher DNA methylation of *HLA-A*, *HLA-B*, and *HLA-C* in IDH-mutant GBMs (current nomenclature is WHO grade IV IDH-mutant astrocytoma). In addition, results were validated by demonstrating an increased expression of the aforementioned genes upon inhibition of methyltransferases in BT142mut IDH-mutant glioma cells [57].

3.2.2. Lower TMB of IDH-mutant gliomas

Lin *et al.* showed a statistically significant higher TMB in IDH-wildtype LGG in comparison to both examined subtypes of IDH-mutant gliomas (P value < 0.0001). While IDH-mutant non-co-deleted group showed an intermediate value of TMB between IDH-wildtype and the IDH-co-deleted mutant; no statistically significant difference was observed between TMB values of the two IDH-mutant subtypes; namely, IDH-mutant glioma with 1p/19q codeletion and IDH-mutant glioma without 1p/19q codeletion [56] (current WHO nomenclatures are oligodendroglioma IDH-mutant and 1p/19q-codeleted, and astrocytoma IDH-mutant, respectively). Similarly, Wang *et al.* reviewed 879 diffuse gliomas (grades II–IV) from the TCGA dataset, including 413 IDH-mutant gliomas, and showed *IDH* mutation to be enriched in tumors with lower TMBs. It could be observed from the plot provided for tumors against their TMBs, that almost all IDH-mutant gliomas have a TMB < 20

mutations/MB, with the vast majority having a TMB < 2 mutations/MB. No more specific conclusions could be made from this analysis, which primarily focused on the association between TMB and clinical outcome of gliomas [58]. In the analysis conducted by Swuala *et al.*, as expected, PMMRDIA ($n = 17$) was reported to have higher TMB in comparison to all other subtypes of MMR-proficient IDH-mutant gliomas ($n = 63$). Remarkably, all analyzed PMMRDIA tumors had a TMB < 30 mutation/MB [14], which is considerably lower than what is known for TMB of other IDH-wildtype dMMR gliomas. A comprehensive analysis of hypermutation in human cancer by the IRRDC has defined two subgroups of dMMR gliomas, with an average TMB of 380 mutation/MB and 80 mutation/MB according to the presence or absence of a secondary *POLE* mutation on top of the primary MMR mutation, respectively [59]. Despite the the association between *IDH* mutation with lower TMB illustrated by these three reports, none of the manuscripts provided an explanation or causality of lower TMB by *IDH* mutation. Indeed, *IDH*-induced CIMP creates an abundance of mutational hotspots [60], and therefore, cannot be directly attributed to lower TMB, leaving the cause of the described association elusive. The relationship between CpG methylation and mutational rate is further elucidated in the discussion section.

3.3. IDH-induced inhibition of chemotaxis: quantitative reduction of infiltrating immune cells in TME of IDH-mutant gliomas

In 2017, Amankulor *et al.* conducted a stepwise comprehensive analysis reporting downregulation of leukocyte chemotaxis in IDH-mutant gliomas, attributing it to *IDH1* mutation. First, they started with fluorescence-activated cell sorting (FACS) analysis (i.e., flow cytometry) of 10 IDH-wildtype and six IDH-mutant human glioma tissue samples, demonstrating fewer overall CD45⁺ immune cell infiltration. Further subset analysis of immune cells showed global depletion of immune infiltrates, including microglia, macrophages, dendritic cells, B cells, and T cells, compared to that of the IDH-wildtype human gliomas. Second, differential gene expression of 91 IDH-wildtype and 417 IDH-mutant grade II/III gliomas from TCGA, using a threshold of two-fold or greater and an adjusted significance P -value < 0.05 , identifying 1297 downregulated genes in IDH-mutant glioma, including genes related to chemotaxis and immune migration, according to gene ontology (GO) terms [61]. Methylation analysis of identified genes was not

conducted. Third, to examine if this effect is due to *IDH1* mutations, they created isogenic IDH-wildtype and IDH-mutant mouse glioma models whose initiating events were identical except for the expression of *IDH1* mutation. It was proved that IDH-mutant mouse gliomas had higher levels of R-2-HG and DNA methylation than their wildtype counterparts. Further analysis of RNA expression data showed downregulation of some immune system processes in the IDH-mutant mouse model, overlapping in part with identified genes from TCGA, suggesting a causal relationship between *IDH1* mutation and the identified pattern of differential gene expression. Subsequently, flow cytometry was conducted to profile the immune cells present in normal mouse brain tissue, IDH-mutant, and IDH-wildtype gliomas. Here, similar to human IDH-mutant gliomas, a reduction in microglia, macrophages, monocytes, and polymorphonuclear leukocytes was observed. This was observed in addition to a negative correlation with leukocyte chemotaxis and neutrophil chemotaxis, as manifested by a Boyden chamber experiment, where cells were plated on the top of a Boyden chamber, incubated, and observed for migration, showing twice as high migration index for the IDH-wildtype mouse gliomas. Furthermore, quantitative PCR (qPCR) showed downregulation of several cytokines; including CCL-2, CCL-3, CXCL-1, CXCL-2, CXCL-4, CXCL-16, GM-CSF, IL-1ra, IL-2, IL-6, IL-16, and others. Finally, expression of these chemokines was investigated in human glioma cell lines, showing higher cytokine expression in the three patient-derived IDH-wildtype human glioma lines from three independent patients (U3039, U3046, and U3065) in comparison to a patient-derived IDH-mutant glioma cell line (TS603). This systematic approach proved that *IDH1* mutation is attributed to decreased chemotaxis in IDH-mutant gliomas leading to decreased immune cell infiltration [62].

In 2017, another key paper by Kohanabash *et al.* described decreased chemotaxis of type 1 CD8⁺ T cells in IDH-mutant glioma, due to downregulation of STAT1, a regulator of CXCL10, which is a chemokine of type 1 CD8⁺ T cells, that predominantly secretes interferon (IFN)- γ [63]. They conducted a systematic multi-step validation design comparable to the previously described study by Amankulor *et al.* [62], in addition to conducting a methylation analysis showing the described gene downregulation not to be related to epigenetic regulation [63]. An additional validation step was conducted by Kohanabash *et al.* [64], by reversing the described reductions in CXCL10 and T cell accumulation by a specific inhibitor of mutant *IDH1*.

Similarly, Ren *et al.* reported decreased expression of different immune cell-related genes, including CD8 (*CD8A*), *CD4*, *CD19*, *CD20* (*MS4A1*), *CD11b* (*ITGAM*), *FOXP3*, *CD163*, *CD68*, *CD56* (*NCAM1*), and *S100A4* in IDH-mutant glioma datasets of TCGA ($n = 390$) and CGGA ($n = 312$). However, their report primarily centered around the expression of the chemokine CX3CL1, which was the only chemokine with increased expression in IDH-mutant glioma in comparison to IDH-wildtype. Ren *et al.* suggested that CX3CL1 plays a role in promoting the recruitment of NK cells, based on its correlation with the higher levels of expression of the NK cell marker, CD56, in IDH-mutant gliomas. Noteworthy, the statistical significance of this correlation was only observed in their analysis of the dataset from the CGGA but not TCGA [65]. Regardless of this suggested quantitative increase of NK cells in the TME of IDH-mutant glioma, Zhang *et al.* [66] explained how *IDH* mutation allows immune escape from NK cell immunity, as explained in Section 3.4.3.

To conclude, the collective evidence indicates that TME of IDH-mutant glioma is less infiltrated with immune cells due to IDH-induced downregulation of chemokines, which in the case of STAT1, was shown not to be related to methylation [63]. However, the methylation effect was not examined in the other reports addressing other chemotaxis-related genes [62,65].

3.4. Dysfunction of various immune cell components

3.4.1. IDH-induced suppression of anti-tumor T cell immunity

One year after the description of reduced T cell infiltrates in IDH-mutant glioma due to decreased chemotaxis, Bunse *et al.* described IDH-induced decreased activation and proliferation of T cells. They were the first to describe a paracrine import mechanism of R-2-HG to T lymphocytes through sodium-dependent SLC13A3 transporter [28]. First, they reported extracellular levels of R-2-HG to be fivefold higher than inside glioma cells. Later, they showed a concentration-dependent increase in intracellular R-2-HG levels in human T cells, and in murine antigen-presenting cells after exposure to R-2-HG. Further analyses of tumor cell lines showed a positive correlation between R-2-HG uptake and the expression of sodium-dependent SLC13A3. Results were validated by reporting a 65% decrease in R-2-HG import upon sodium starvation, and by reporting a decrease in intracellular R-2-HG levels, in a concentration-dependent manner when treated with an SLC13A3

inhibitor. Consequently, Bunse *et al.* showed reduced antigen-specific proliferation and cytokine secretion of mouse T cell receptor (TCR) transgenic CD4⁺ T cells and TCR transgenic CD8⁺ T cells when exposed to R-2-HG *in vitro*. Next, they reported that human T cells from an IDH-mutant glioma patient showed a concentration-dependent reduction of *IDH1* R132H-specific IFN- γ production, which was also validated in a transgenic mouse model generated by them. Two types of cell cultures were produced; the first was made of activated primary mouse T cells co-cultured with IDH-mutant astrocytes, and the second was composed of mouse T cells co-cultured with IDH-wildtype astrocytes. The former showed the lower capacity to produce the effector cytokines IFN- γ and IL-2 after activation. Finally, investigators attributed T cell suppression to IDH-induced alteration in calcium signaling. They observed differential downregulation of calcium-dependent transcriptional activity of nuclear factor of activated T cells (NFAT) and NF- κ B, which are required for the transcription of IL-2 [67], and interact with the promoter of IFN- γ [68]. Then detected R-2-HG-mediated suppression of extracellular calcium influx in stimulated CD4⁺ T cells by fura-calcium imaging. To validate their hypothesis and assess whether the observed moderate intracellular calcium alterations are sufficient to induce the inhibitory effect on T cell proliferation, *in-vitro* rescue experiments were conducted, restoring T cell proliferation with increasing concentrations of calcium in activated human T cells. Results were further validated in MHC-humanized A2DR1 mice models they had previously generated [69], revealing reduced infiltration and activation of T cells, reduced IFN- γ production, and reduced levels of NFAT. Despite that the model is generated from sarcoma cells, it supported the molecular effect of an *IDH* mutation. Noteworthy, Bunse *et al.* attributed their findings to R-2-HG metabolic regulation of T cells, as no epigenetic reprogramming of T cells was observed *in vitro* [28]. In addition to the R-2-HG induced decreased production of T cell cytokines proposed by Bunse *et al.*, Notarangelo *et al.* showed R-2-HG to decrease degranulation of CD8⁺ T cells in a dose-dependent manner, further impairing IFN- γ signaling pathway. Their results were examined *in vitro* by restoring the ability of CD8⁺ T cells to degranulate upon R-2-HG removal at the time of T cell stimulation. In addition, they reported and validated several R-2-HG-induced metabolic derangements on T cells; consistent with the described metabolic effect of *IDH* mutation on tumor cells themselves (Section 1) [39]. Recently, a more focused analysis conducted by Afsari *et al.*, investigating R-2-HG-induced

effect on IL-2, showed a concentration-dependent inhibitory effect on its release, supporting the results of Notarangelo *et al.*, together with suppressed NFAT-dependent transcription, consistent with the results of Bunse *et al.* [40]. In summary, in addition to decreased T cell chemotaxis through IDH-induced downregulation of STAT1, R-2-HG gets imported into the T cells through sodium-dependent transporter, where it exerts metabolic downregulation of calcium-dependent transcription factors decreasing IL-2 and IFN- γ production. Furthermore, it interferes with T cell degranulation of these cytokines, further impairing T cell responses.

3.4.2. IDH-induced immune escape from natural killer cell immunity

In 2016, Zhang *et al.* [66] conducted a multistep validation design study, suggesting that IDH-mutant gliomas escape NK cell immune surveillance by downregulating NK group 2D ligand (NKG2DL). NKG2DL are membrane-bound proteins expressed on tumor cell surfaces that are recognized by NKG2D receptors on NK cells and CD8⁺ T cells, mediating cytotoxic immune recognition, independent of tumor-specific antigens. Zhang *et al.* first observed downregulation of NKG2DL by analyzing RNA-seq data from 286 diffuse glioma patient samples from TCGA, which was also correlated with promoter hypermethylation. Second, they validated their results by examining the differential expression level of NKG2DL in IDH-mutant and wildtype glioma cell lines, with the former exhibiting > 5 times lower expression (*P* value < 0.001). Thirdly, they validated their conclusion by performing mixed allogeneic co-cultures of donor NK cells and IDH-mutant/wildtype astrocytes, and imaged astrocytes using phase-contrast micrography after 72 h of co-culture, showing 97% of the IDH-mutant astrocytes to be viable and adherent, compared to 54% of wildtype astrocytes (*P* value = 0.01). As they attributed their results to DNA hypermethylation, they concluded their study by applying decitabine-mediated hypomethylation to restore expression in IDH-mutant glioma cells, suggesting its clinical potential to sensitize IDH-mutant gliomas to NK cell-mediated immune surveillance in patients with IDH-mutant gliomas [66]. Hence, the focus of Zhang *et al.* was not to assess the direct effect of R-2-HG on NK cells, but rather their impaired binding to tumor cells, which was attributed to ligand impairment on the tumor sites and not NK cells. None of the identified studies examined if R-2-HG was imported into NK, or studied its direct effect on NK cells.

3.4.3. R-2-HG limits the activation and antigen presentation by dendritic cells

Similar to T-cells, dendritic cells (DCs) are capable of uptaking R-2-HG, as shown by Ugele *et al.* in 2019 [70], which reported a 100-fold increase in the intracellular levels of R-2-HG in DCs under treatment with 10 mM R-2-HG. However, mechanistic insights of this intracellular uptake remained elusive. Subsequently, they showed downregulation in IL-12 levels owing to the intracellular accumulation of R-2-HG. Notably, IL-12 plays a crucial role in T cell activation by improving the type 1 T helper cell response, promoting the expansion and survival of activated T cells and NK cells, enhancing CD8⁺ T cell homeostatic expansion, leading to enhanced TCR-induced signaling and cytokine production, and increasing CD8⁺ T cell cytotoxicity, survival, and proliferation [71,72]. Ugele *et al.* conducted their analysis on leukapheresis-isolated peripheral blood mononuclear cells of consented healthy donors from the University Hospital Regensburg. They first showed decreased mRNA expression of both *IL-12A* and *IL-12B* genes post-R-2-HG treatment in a dose-dependent manner. While expression levels of *IL-12A* and *IL-12B* genes were significantly decreased 4 h after the treatment, the effect returned to baseline level in 24 h for *IL-12A*, but persisted for *IL-12B*. While the report described reduced secretion of IL-12 from DCs after R-2-HG treatment, the underlying cause for reduction in IL-12 secretion remains unclear. While no methylation analysis was conducted in this study, investigators attributed their findings to the metabolic effect of R-2-HG and validated this based on the fact that lipopolysaccharide (LPS) is a potent stimulant of DCs [73]. Considering that, Ugele *et al.* showed that R-2-HG reverses the effect of LPS on cellular respiration which promotes DC stimulation. Finally, they showed that the addition of ATP synthase inhibitor, oligomycin, to DC cultures to increase IL-12 secretion, partially reverted the effect of R-2-HG. This suggested that R-2-HG-induced changes in cellular respiration may contribute to the diminished IL-12 secretion [70]. In 2022, Friedrich *et al.* suggested that the biological function of DCs in glioma is not restricted to priming peripheral T cells, but rather blood-borne monocytes accumulate intratumorally during glioma progression and experience a glioma genotype-dependent DC education. Altogether, this might result in diverging immunological capacities, which is not the scope of this systematic review [74].

3.4.4. IDH-induced effects on macrophages

In 2018, Gowda *et al.* described decreased CD47 expression and its role in IDH-mutant glioma, by

examining mRNA expression *in vitro* and *in silico* utilizing the TCGA dataset. Given that CD47 is a transmembrane glycoprotein in a tumor cell that delivers an inhibitory signal for macrophage phagocytosis, they subsequently examined microglia's capability to engulf IDH-mutant cells with reduced CD47 levels. As expected, microglia exhibited a stronger phagocytic response toward the U87MG cells overexpressing mutant *IDH1* compared to cells expressing wildtype *IDH1* [75]. No methylation analysis was conducted in this study. Notably, tumor-associated microglia/macrophages (TAMs) are the main innate immune effector cells in malignant gliomas, and they have both pro- and anti-tumor functions, with their plasticity being partially dictated by underlying oncogenic mutations [76]. This finding of Gowda *et al.* was further supported by Ma *et al.* [76], which demonstrated for the first time that glioma cells carrying heterozygous *IDH1* R132H mutation switch TAMs toward a phagocytic anti-tumor phenotype by downregulating ICAM1/CD54 pathway. Similar to Gowda *et al.*, Ma *et al.* also validated their findings *in vitro* and *in silico* utilizing the TCGA dataset. Similar to CD47, ICAM1 is expressed on the tumor cells and not the macrophages. Ma *et al.* [76] additionally examined the methylation data and attributed *ICAM1* downregulation to hypermethylation of its promoter. In conclusion, both studies suggest enhanced anti-tumor phagocytic activity of microglia in IDH-mutant glioma in comparison to IDH-wildtype, which contributed to better prognosis of the former. Noteworthy, both studies addressed the modulation of tumor cell's ligands interacting with microglia, but did not examine additional direct effects of R-2-HG on TAMs themselves, which might provide more insights into the immune function of TAMs in the TME of IDH-mutant gliomas.

3.5. Downregulation of immune checkpoints

3.5.1. Epigenetic downregulation of PDL-1

Downregulation of PDL-1 in IDH-mutant glioma was first described in 2016 by Wang *et al.*, which analyzed transcriptomic data of 976 glioma samples of grades II–IV, including 301 microarray data from the CGGA project and 675 RNA-seq data from TCGA. Their analyses showed that IDH-mutant glioma has lower expression of PD-L1 (*CD274*) in comparison to IDH-wildtype, across all grades, with significant adjusted *P*-value of < 0.05 for grade IV (both CGGA and TCGA), and grade III (TCGA). No methylation data were analyzed in this study [77]. Similarly, Berghoff *et al.* reported statistically significant (*P* < 0.001)

higher PD-L1 expression among all grades (grades II–IV) of Vienna glioma cohort [$n = 174$, composed of 43 WHO grade II/III gliomas and 131 GBM (current nomenclature is WHO grade IV diffuse glioma)]. In addition, they examined a subset of glioma from the TCGA database for which the methylation data together with RNA-seq data ($N = 51$ IDH-wildtype and 4 IDH-mutant) was available. Resultant analyses showed a reduced PD-L1 gene expression associated with increased promoter methylation (Spearman correlation coefficient -0.36 ; $P < 0.01$) in the LGG cohort [45]. In 2018, Mu *et al.* concluded the same results by examining tumors from 35 adult patients with WHO grade II/III glioma together with 15 primary GBMs (current nomenclature is WHO grade IV diffuse glioma) from three Chinese hospitals. Furthermore, IDH-wildtype tumors showed relatively higher levels of PD-L1 gene and protein levels in both primary LGGs and GBMs (current nomenclature is WHO grade IV diffuse glioma) as compared to IDH-mutant tumors. While their analyses did not provide specific P values, they identified two CpGs within the PD-L1 promoter (cg15837913 and cg19724470) that exhibited differential methylation patterns between normal brains and tumors as well as IDH-mutant and wild-type gliomas. Subsequently, they validated their findings *in vitro*, by adding R-2-HG (0, 3, or 6 mM) daily to the cell culture of an IDH-wildtype GBM line U87. They observed a transient increase in DNA methylation of both CpG sites 24 h after R-2-HG was added. However, DNA methylation was reversed at 48 h, in addition to a surge in DNA methylation beta-value of the non-treated cells at the same time point. Investigators could not provide an explanation for the results observed at 48 h, as mechanisms underlying the dynamic methylation patterns that dictate spatial and temporal gene expression are still not completely understood [78]. In 2021, Kadiyala *et al.* supported the previous findings by showing an increased PD-L1 expression in response to R-2-HG inhibition, up to similar levels as observed in IDH-wildtype gliomas. Interestingly, they already combined R-2-HG inhibition with radiotherapy, TMZ, and anti-PDL1 ICB, and observed complete tumor regression in 60% of IDH-mutant glioma-bearing mice. Based on their results, they propose utilization of IDH inhibitor and ICB in the clinical practices to treat IDH-mutant glioma [79], which indeed would be particularly valuable for the PMMRDIA group, which is otherwise resistant to TMZ. Noteworthy, Suwala *et al.* [14] also reported PMMRDIA tumors to have scarce or no expression of PD-L1 in a small percentage of tumor cells. Despite this, the molecular pathways and TME of this

particular group of IDH-mutant glioma are not yet known to us.

3.5.2. Downregulation of other immune checkpoints

In 2018, Röver *et al.* expanded RNA expression analysis and DNA promoter methylation analysis to more ICB-related genes including PD-L1 (*CD274*), PD-1 (*PDCDI*), PD-L2 (*PDCD1LG2*), and CTLA-4 (*CTLA4*), utilizing data from TCGA, focusing on subgroups of IDH-mutant LGGs ($n = 419$). They first showed a statistically significant inverse correlation of mRNA expression levels with promoter methylation for the three genes related to PD-L1, PD-L2, and CTLA-4. Subsequently, they analyzed the difference in methylation among three methylation classes of LGGs: LGm1, LGm2, and LGm3 (according to classification by Ceccarelli *et al.* [80]); while exact corresponding WHO classes are not clear from Ceccarelli's paper, it could be understood that LGm3 is 1p/19q co-deleted, and both LGm1 and LGm2 are non-co-deleted, with enrichment of pediatric cases among LGm1 group [80]. Among the three studied groups, promoter methylation of all PDL-1, PDL-2, PD-1, and CTLA-4 was the lowest in LGm1. In addition, they correlated methylation patterns of examined checkpoints to various clinical and molecular characteristics of gliomas, where PD-1 methylation qualified as a strong prognostic factor together with age [81]. The latter finding was supported by Liu *et al.* in 2020, who showed upregulation of PD-1 expression in IDH-mutant GBM (current nomenclature is WHO grade IV IDH-mutant astrocytoma) and IDH-wildtype GBM, based on their analysis of PD-1 transcriptional expression data of 1323 glioma from the CGGA and TCGA datasets and a local hospital cohort. No methylation analysis was conducted, and no validation was done, as the focus of the analysis was on the correlation between expression pattern and clinical behavior [82]. Another protein of the B7 family of checkpoints, B7H3, has the highest expression compared to other members of the B7 family in GBM (current nomenclature is WHO grade IV diffuse glioma) as shown by Zhang *et al.* [83]. In a subsequent study, the same group examined its differential expression according to *IDH* status, and showed statistically significant lower mRNA expression in IDH-mutant LGG of TCGA cohort in comparison to IDH-wildtype, together with lower expression in IDH-mutant GBM (current nomenclature is WHO grade IV IDH-mutant astrocytoma) of TCGA, without statistical significance due to small number. Additionally, they showed lower protein expression in fresh tumor samples, as well as glioma cell line U87 treated with cell-permeable 2-HG [84].

Consistent with its previously identified involvement in angiogenesis in pancreatic and colorectal carcinoma [85,86], Zhang *et al.* [84] also showed that B7H3 expression correlates with VEGFA and MMP2 expression, which are all downregulated in IDH-mutant LGG, based on the mRNA data analysis of the TCGA dataset and reduced protein levels in *IDH1* R132H U87 cells compared to its wildtype counterparts. Furthermore, given the galectin-9 (Gal-9)/T cell immunoglobulin and mucin-domain containing-3 (TIM-3) pathway is gaining significant attention in cancer immunotherapy as an additional inhibitory checkpoint system, its expression in IDH-mutant glioma was also examined by Sørensen *et al.* in 2020. It is understood that TIM-3 is present in various T cell subsets and plays a crucial role in promoting T cell tolerance through its interactions with ligands, including Gal-9. In addition, TIM-3 has been associated with T cell exhaustion and dysfunction, particularly when expressed alongside PD-1. In the analysis conducted by Sørensen *et al.* on a local cohort of grades III/IV glioma (36 IDH-mutant and 36 IDH-wildtype) together with a validation TCGA cohort, *IDH* mutation was significantly linked to lower levels of TIM-3⁺ cells and decreased interactions between TIM-3⁺ T cells and galectin-9⁺ microglia/macrophages, as shown by lower TIM-3 mRNA expression and IHC staining. No methylation analysis was conducted, and no validation was conducted *in vitro* or *in vivo* to show a direct effect of *IDH* mutation on the expression of TIM-3 [87].

4. Discussion

IDH-mutant gliomas are characterized by an immunosuppressive TME. By conducting a systematic review summarizing available evidence of *IDH*-induced effects on the immunogenicity of IDH-mutant glioma, three main mechanisms were identified; namely, (a) epigenetic, (b) metabolic, and (c) paracrine. Extracted evidence from the 23 studies included in this systematic review are classified into nine categories. The first two categories are related to decreased antigen presentation either by decreased MHC expression, or lower TMB. In addition to the described methylation-induced downregulation of MHC class I molecules by Luoto *et al.*, it could be argued that G-CIMP might promote a more generalized gene silencing of various cancer-associated neoantigens, similar to the hypermethylation of CpG islands located at the promoters of melanoma-associated antigens (MAGE) and other cancer testis antigens (CTA), presenting a common mechanism of their downregulation in various solid tumors and hematologic malignancies [88,89]. To the best of our knowledge, this effect has not been studied in

IDH-mutant glioma, despite their characteristic G-CIMP phenotype.

While our results show an association between *IDH* mutation and lower TMB in comparison to IDH-wildtype gliomas of comparable MMR status, the underlying mechanisms responsible for this association remain unclear. It is understood that IDH-induced G-CIMP have abundant mutational hotspots which cannot be attributed to lower TMB of IDH-mutant gliomas. 5-Methylcytosine (5-mC) is the most common DNA modification found in the eukaryotic genome, and it is estimated that ~90% of 5-mC occur within the CpG dinucleotides in vertebrate genomes [60]. Likewise, it is thought that the majority of Cs within CpGs are methylated [60]. While C is the most unstable nucleobase, 5-mC is considered even more prone to spontaneous deamination [90–92], producing 5-mC>T mutations, which predominate the spectra of spontaneous base substitutions in mammalian cells as well as in *Escherichia coli* [93]. In fact, unmethylated C deaminates to Uracil (U), while 5-mC deaminates to T [4]. The latter event results in difficult-to-repair mismatches [93], which further explains why CpGs are considered mutational hot spots, harboring around 35% of all mutational events of the genome [60]. In addition to spontaneous cytosine deamination, cells additionally incur a large number of G:C>A:T transitions upon DNA replication, throughout the whole genome (not concentrated in CpGs). These become particularly abundant in the case of deficient MMR machinery, where they are estimated to occur at a significantly higher rate than spontaneous deamination of 5-mC which concentrates at CpG dinucleotides [94]. This is why hypermutation is defined not only by the abundance of mutations but also by a strong signature of G:C>A:T transitions at CpG and non-CpG sites [12]. Indeed, the three identified studies addressing lower TMB in IDH-mutant gliomas suggest that there must be a mechanism other than G-CIMP affecting the mutational rate in IDH-mutant glioma. The presumed mechanism might be decreasing the rate of replication errors in non-CpG sites. Indeed, there are several other characteristic genetic and epigenetic mechanisms in IDH-mutant gliomas that could affect the rate of DNA replication, such as histone methylation and *ATRX*-induced chromatin modulation, whose effect on TMB of IDH-mutant glioma is not examined in this systematic review addressing the effect of *IDH* mutation itself.

Thirdly, decreased chemotaxis of various types of immune cells was well elaborated by the two milestone studies of Amankulor *et al.* and Kohanabash *et al.* Ren *et al.* also supported the findings of the previous

two groups on a generalized decrease in chemotaxis and suggested an increased chemotaxis of NK cells to IDH-mutant gliomas. Regardless of this, Zhang *et al.* explained how *IDH* mutation allows immune escape from NK cell immunity by downregulating NKG2DL, which is the fourth aspect identified by our systematic review. NKG2DL expression is stress-induced and is known to occur following oncogenic transformation regardless of specific tissue type [95]. It is not surprising that its downregulation has been described as an immune escape mechanism in other cancers as well [96–98]. Similar to IDH-mutant glioma, its downregulation by methylation has also been described in AML [98]. Fifth, decreased interaction with immune cells in the two papers addressing downregulation of CD47 and ICAM1 results in an increased phagocytic activity of TAMs. Indeed, the expression of CD47 is a general mechanism through which human solid tumor cells evade phagocytosis [99]. Similarly, ICAM1 is a member of the immunoglobulin supergene family that interacts with β 2 integrins, and plays a critical role in suppressing immune activation and inflammation [100]. Against a vast majority of evidence consistent with immune suppressive effect of *IDH* mutation, Gowda *et al.* and Ma *et al.* identified that the anti-tumor phagocytic activity of microglia could be attributed to a better prognosis of IDH-mutant gliomas in comparison to IDH-wildtype.

Sixth and seventh, in contrast to studies addressing NK and TAM immunity only from the angle of their interaction with tumor ligands, import of R-2-HG to T cells and dendritic cells has been well studied, where it has been found to exert significant metabolic and functional derangements contributing to immunosuppressive effect. Indeed, elevated serum levels of R-2-HG have been reported in several types of IDH-mutant tumors [25–27], explaining how the net outcome of R-2-HG accumulation results in survival benefit of tumor cells, despite its potential to disturb several metabolic pathways, thereby, diminishing cellular fitness. It would not be surprising if R-2-HG was similarly identified to be imported into NK cells and TAMs, where it could further affect their immunological function. In addition, R-2-HG might also be imported into tumor cells of the subclones lacking *IDH* mutation, within IDH-mutant gliomas, exerting its epigenetic and metabolic effect there as well. Altogether, this, in part, explains how an *IDH* event in a glioma behaves in a predominant manner to exert distinguished molecular and metabolic phenotypes.

Eighth and most interestingly, the downregulation of PDL-1 within IDH-mutant gliomas, which could be directly responsible for the resistance of IDH-mutant

gliomas to Nivolumab, including PMMRDIA. Based on the literature, not enough evidence was found to validate the causal effect of *IDH* mutation in downregulating PDL-1 expression. While this is not a counterargument, *in vitro* or *in vivo* validation along with testing the efficacy of proposed combination therapy of a DNA methylation inhibitor or an IDH inhibitor in combination with ICB is warranted. Lastly, other immune checkpoints were found to be downregulated in IDH-mutant gliomas, due to hypermethylation, with some variation in the degree of downregulation between different subclasses. This suggests that astrocytoma has a more prominent downregulatory effect of the various studied immune checkpoints shown by Röver *et al.*, in comparison to 1p/19q co-deleted oligodendroglioma, which is particularly pertinent in PMMRDIA. Taken together, these findings will guide the use of various ICB-based treatment options.

5. Conclusions and perspective

In conclusion, the downregulatory effect exerted on immune-related genes of IDH-mutant glioma cells is attributed to hypermethylation; including downregulation of MHC class I molecules, NKG2DL interaction with NK cells, interaction of CD47 and ICAM1 with TAMs, together with downregulation of immune checkpoints such as PDL-1 and PDL-2. This is not surprising given the characteristic G-CIMP, which might additionally affect the expression of other tumor antigens. While paracrine effect of R-2-HG on immune cells was primarily metabolic rather than epigenetic, the downregulation of PD-1 and CTLA4, which are expressed on immune cells, can be attributed to hypermethylation, suggesting that R-2-HG could also lead to epigenetic reprogramming in a paracrine manner, as summarized in Table 1. In the last decade, precision therapeutics targeting *IDH* mutation and DNA methylation have been employed as differentiation agents in cancer treatment, and have been approved by the Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome (MDS) and AML [101,102]. In IDH-mutant gliomas, both modalities have shown promising results in pre-clinical and clinical trials [103,104]. It could be argued that while epigenetic modulators may effectively counteract the hypermethylation phenotype associated with an *IDH* mutation, their impact on other cancer-related features in IDH-mutant tumors, such as metabolic reprogramming and DNA repair pathways, remains uncertain [11].

In addition to their anti-tumorigenic effect, it can be deduced that both *IDH* and methylation inhibitors aid

in the management of IDH-mutant glioma by additionally modulating its TME, as summarized in Table 1. In the contemporary landscape of advancing combinatorial therapeutic approaches with ICB to enhance efficacy and tackle resistance, the potential combination of *IDH* inhibitors and/or methylation inhibitors with ICB emerges as a promising strategy for IDH-mutant gliomas generally, and specifically for PMMRDIA; where it holds particular promise, addressing the dual resistance of PMMRDIA to ICB and the standard-of-care chemotherapeutic agent TMZ. Indeed, the efficacy of methylation inhibitors in combination with ICB has been already examined in several other malignancies [105–108]. While our review focused on the potential of using an *IDH* inhibitor and/or a methylation inhibitor in combination with an ICB, there are other IDH-targeted therapeutics including the *IDH1* R132H specific vaccine [4,109], which could be used as alternative therapy options.

However, there are two major limitations of this systematic review. First, we aimed at collecting comprehensive evidence regarding the effect of *IDH* mutation on the immunogenicity of glioma, and therefore, excluded manuscripts that did not directly address the effect of *IDH* mutation. While this strategy helped to maintain the focus of our review, it would be useful to comprehend our results together with the collective available evidence regarding the immune effect of other known driver mutations accompanying *IDH* mutation in glioma, such as *ATRX*. Based on our PRISMA statement, (Fig. 3) eleven manuscripts were excluded from this review for this reason. Secondly, while we aim at exploiting the extracted evidence, to suggest a preclinical trial of a combinational regimen composed of an *IDH* inhibitor and/or methylation inhibitor together with an ICB for PMMRDIA, it needs to be taken into consideration that PMMRDIA has a distinct methylation profile that clusters separately from other groups of IDH-mutant glioma, and therefore some of the identified findings regarding methylation-induced downregulated genes might not hold true for PMMRDIA; thus, these need to be tested in methylation data of the PMMRDIA cohort. However, the majority of our findings were already validated *in vitro* and/or *in vivo* for their causal relationships with an *IDH* mutation, and therefore are likely to be true for PMMRDIA too.

On the other hand, this is the first systematic review summarizing the effect of *IDH* mutation on the immunogenicity of IDH-mutant gliomas. It is also the first manuscript providing insights regarding the unmet therapeutic challenge of PMMRDIA, suggesting a pre-clinical trial to evaluate the effectiveness of a

combination therapy involving an ICB in conjunction with an *IDH* inhibitor or DNA methylation inhibitor for PMMRDIA.

Acknowledgements

Not applicable.

Conflict of interest

None.

Author contributions

O.A. conceptualized the work, carried out the title and abstract screening together with full-text screening, extracted data, drafted the manuscript, and created the illustrations. T.A. carried out title and abstract screening and reviewed the manuscript. S.M.P. reviewed the manuscript. All authors have reviewed and agreed on the final version of the manuscript.

References

- 1 Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. *Science*. 2007;**318** (5853):1108–13.
- 2 Borger DR, Zhu AX. IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications. *Expert Rev Anticancer Ther*. 2012;**12**(5):543–6.
- 3 Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. *J Clin Oncol*. 2010;**28**(22):3636–43.
- 4 Waitkus MS, Diplas BH, Yan H. Biological role and therapeutic potential of IDH mutations in cancer. *Cancer Cell*. 2018;**34**(2):186–95.
- 5 Yang P, Zhang W, Wang Y, Peng X, Chen B, Qiu X, et al. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. *Oncotarget*. 2015;**6**(38):40896–906.
- 6 Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science*. 2008;**321** (5897):1807–12.
- 7 Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. *N Engl J Med*. 2009;**360**(8):765–73.
- 8 Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016

- World Health Organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol.* 2016;**131**(6):803–20.
- 9 Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro-Oncology.* 2021;**23**(8):1231–51.
 - 10 Alshiekh Nasany R, de la Fuente MI. Therapies for IDH-mutant gliomas. *Curr Neurol Neurosci Rep.* 2023;**23**(5):225–33.
 - 11 Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. *Br J Cancer.* 2020;**122**(11):1580–9.
 - 12 Choi S, Yu Y, Grimmer MR, Wahl M, Chang SM, Costello JF. Temozolomide-associated hypermutation in gliomas. *Neuro-Oncology.* 2018;**20**(10):1300–9.
 - 13 Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med.* 2005;**352**(10):987–96.
 - 14 Suwala AK, Stichel D, Schrimpf D, Kloor M, Wefers AK, Reinhardt A, et al. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. *Acta Neuropathol.* 2021;**141**(1):85–100.
 - 15 Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. *Clin Cancer Res.* 1998;**4**(1):1–6.
 - 16 Loveless A. Possible relevance of O-6 alkylation of deoxyguanosine to the mutagenicity and carcinogenicity of nitrosamines and nitrosamides. *Nature.* 1969;**223**(5202):206–7.
 - 17 Roos WP, Batista LFZ, Naumann SC, Wick W, Weller M, Menck CFM, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. *Oncogene.* 2007;**26**(2):186–97.
 - 18 Amayiri N, Tabori U, Campbell B, Bakry D, Aronson M, Durno C, et al. High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. *Int J Cancer.* 2016;**138**(2):380–5.
 - 19 Aronson M, Colas C, Shuen A, Hampel H, Foulkes WD, Baris Feldman H, et al. Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group. *J Med Genet.* 2022;**59**(4):318–27.
 - 20 DKFZ-German Cancer Research Center. MNP classifier. Available from: <https://www.molecularneuropathology.org/mnp/classifiers>.
 - 21 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med.* 2015;**372**(26):2509–20.
 - 22 Das A, Tabori U, Sambira Nahum LC, Collins NB, Deyell R, et al. Efficacy of nivolumab in pediatric cancers with high mutation burden and mismatch-repair deficiency. *Clin Cancer Res.* 2023;**29**:4770–83.
 - 23 SK Hospital. International replication repair deficiency consortium. 2023; Available from: <https://replicationrepair.ca/>.
 - 24 Koh HJ, Lee SM, Son BG, Lee SH, Ryoo ZY, Chang KT, et al. Cytosolic NADP⁺-dependent isocitrate dehydrogenase plays a key role in lipid metabolism. *J Biol Chem.* 2004;**279**(38):39968–74.
 - 25 Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature.* 2010;**465**(7300):966.
 - 26 DiNardo CD, Probert KJ, Loren AW, Paietta E, Sun Z, Levine RL, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. *Blood.* 2013;**121**(24):4917–24.
 - 27 Emir UE, Larkin SJ, de Pennington N, Voets N, Plaha P, Stacey R, et al. Noninvasive quantification of 2-Hydroxyglutarate in human gliomas with IDH1 and IDH2 mutations. *Cancer Res.* 2016;**76**(1):43–9.
 - 28 Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. *Nat Med.* 2018;**24**(8):1192–203.
 - 29 Leca J, Fortin J, Mak TW. Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers. *Curr Opin Biotechnol.* 2021;**68**:181–5.
 - 30 Kim MM, Parolia A, Dunphy MP, Venneti S. Non-invasive metabolic imaging of brain tumours in the era of precision medicine. *Nat Rev Clin Oncol.* 2016;**13**(12):725–39.
 - 31 Izquierdo-Garcia JL, Viswanath P, Eriksson P, Chaumeil MM, Pieper RO, Phillips JJ, et al. Metabolic reprogramming in mutant IDH1 glioma cells. *PLoS One.* 2015;**10**(2):e0118781.
 - 32 Fujii T, Khawaja MR, DiNardo C, Atkins JT, Janku F. Targeting isocitrate dehydrogenase (IDH) in cancer. *Discov Med.* 2016;**21**(117):373–80.
 - 33 Koh KP, Yabuuchi A, Rao S, Huang Y, Cuniff K, Nardone J, et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. *Cell Stem Cell.* 2011;**8**(2):200–13.
 - 34 Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. *EMBO Rep.* 2011;**12**(5):463–9.
 - 35 Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. *Nature.* 2012;**483**(7390):479–83.
 - 36 Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone

- demethylation and results in a block to cell differentiation. *Nature*. 2012;**483**(7390):474–8.
- 37 Turcan S, Fabius AWM, Borodovsky A, Pedraza A, Brennan C, Huse J, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. *Oncotarget*. 2013;**4**(10):1729–36.
 - 38 Borodovsky A, Salmasi V, Turcan S, Fabius AWM, Baia GS, Eberhart CG, et al. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. *Oncotarget*. 2013;**4**(10):1737–47.
 - 39 Notarangelo G, Spinelli JB, Perez EM, Baker GJ, Kurmi K, Elia I, et al. Oncometabolite d-2HG alters T cell metabolism to impair CD8(+) T cell function. *Science*. 2022;**377**(6614):1519–29.
 - 40 Afsari F, McIntyre TM. D-2-hydroxyglutarate inhibits calcineurin phosphatase activity to abolish NF-AT activation and IL-2 induction in stimulated lymphocytes. *J Immunol*. 2023;**210**(4):504–14.
 - 41 Pushan Dasgupta HL, Soomro Z, Bornstein C, Alfaro-Munoz K, Yuan Y, De Groot J, et al. Clinical and molecular determinants of survival outcomes in glioblastoma patients treated with immune checkpoint inhibitors (S27.007). *Neurology*. 2022;**98**. https://doi.org/10.1212/WNL.98.18_supplement.1517
 - 42 Caroline Dehais FD, Belin L, Frenel J-S, Chinot OL, Carpentier AF, Moyal E, et al. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). *J Clin Oncol*. 2022;**157**:161–6. Meeting Abstract | 2022 ASCO Annual Meeting I.
 - 43 Paracha A, Campian J. The effect of anti-PD-1 therapy on median overall survival and progression free survival in glioblastoma multiforme patients with certain tumor markers. *J Immunother Cancer*. 2020;**8**:A128.
 - 44 Ni L, Sun P, Zhang S, Qian B, Chen X, Xiong M, et al. Transcriptome and single-cell analysis reveal the contribution of immunosuppressive microenvironment for promoting glioblastoma progression. *Front Immunol*. 2022;**13**:1051701.
 - 45 Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. *Neuro-Oncology*. 2017;**19**(11):1460–8.
 - 46 Zhu Y, Feng S, Song Z, Wang Z, Chen G. Identification of immunological characteristics and immune subtypes based on single-sample gene set enrichment analysis algorithm in lower-grade glioma. *Front Genet*. 2022;**13**:894865.
 - 47 Liu Z, Lu T, Wang L, Liu L, Li L, Han X. Comprehensive molecular analyses of a novel mutational signature classification system with regard to prognosis, genomic alterations, and immune landscape in glioma. *Front Mol Biosci*. 2021;**8**:682084.
 - 48 Shen X, Wang X, Shen H, Feng M, Wu D, Yang Y, et al. Transcriptomic analysis identified two subtypes of brain tumor characterized by distinct immune infiltration and prognosis. *Front Oncol*. 2021;**11**:734407.
 - 49 Abedalthagafi M, Barakeh D, Foshay KM. Immunogenetics of glioblastoma: the future of personalized patient management. *NPJ Precis Oncol*. 2018;**2**:27.
 - 50 Wang Y, Luo R, Zhang X, Xiang H, Yang B, Feng J, et al. Proteogenomics of diffuse gliomas reveal molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. *Nat Commun*. 2023;**14**(1):505.
 - 51 Zhang Y, Pan C, Wang J, Cao J, Liu Y, Wang Y, et al. Genetic and immune features of resectable malignant brainstem gliomas. *Oncotarget*. 2017;**8**(47):82571–82.
 - 52 Wang Q, Lin W, Liu T, Hu J, Zhu Y. Immunological classification of glioblastoma and its prognostic implications. *Am J Transl Res*. 2022;**14**(11):8009–22.
 - 53 Haddad AF, Young JS, Oh JY, Okada H, Aghi MK. The immunology of low-grade gliomas. *Neurosurg Focus*. 2022;**52**(2):E2.
 - 54 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Rev Esp Cardiol (Engl Ed)*. 2021;**74**(9):790–9.
 - 55 Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev*. 2016;**5**(1):210.
 - 56 Lin W, Qiu X, Sun P, Ye Y, Huang Q, Kong L, et al. Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma. *Mol Ther Oncolytics*. 2021;**21**:288–302.
 - 57 Luoto S, Hermelo I, Vuorinen EM, Hannus P, Kesseli J, Nykter M, et al. Computational characterization of suppressive immune microenvironments in glioblastoma. *Cancer Res*. 2018;**78**(19):5574–85.
 - 58 Wang L, Ge J, Lan Y, Shi Y, Luo Y, Tan Y, et al. Tumor mutational burden is associated with poor outcomes in diffuse glioma. *BMC Cancer*. 2020;**20**(1):213.
 - 59 Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, et al. Comprehensive analysis of Hypermutation in human cancer. *Cell*. 2017;**171**(5):1042–56.e10.
 - 60 Cooper DN, Youssoufian H. The CpG dinucleotide and human genetic disease. *Hum Genet*. 1988;**78**(2):151–5.
 - 61 The Gene Ontology (GO) Consortium. The gene ontology resource. 2023 [cited 2023]; Available from: <http://geneontology.org/>.
 - 62 Amankulor NM, Kim Y, Arora S, Kargl J, Szulzewsky F, Hanke M, et al. Mutant IDH1 regulates

- the tumor-associated immune system in gliomas. *Genes Dev.* 2017;**31**(8):774–86.
- 63 Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8⁺ T cell accumulation in gliomas. *J Clin Invest.* 2017;**127**(4):1425–37.
 - 64 Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. *J Craniomaxillofac Surg.* 2011;**39**(2):91–2.
 - 65 Ren F, Zhao Q, Huang L, Zheng Y, Li L, He Q, et al. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas. *Immunol Cell Biol.* 2019;**97**(5):457–69.
 - 66 Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, et al. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. *Neuro-Oncology.* 2016;**18**(10):1402–12.
 - 67 Chow CW, Rincon M, Davis RJ. Requirement for transcription factor NFAT in interleukin-2 expression. *Mol Cell Biol.* 1999;**19**(3):2300–7.
 - 68 Sica A, Dorman L, Viggiano V, Cippitelli M, Ghosh P, Rice N, et al. Interaction of NF-kappaB and NFAT with the interferon-gamma promoter. *J Biol Chem.* 1997;**272**(48):30412–20.
 - 69 Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. *Nature.* 2014;**512**(7514):324–7.
 - 70 Ugele I, Cárdenas-Conejo Z, Hammon K, Wehrstein M, Bruss C, Peter K, et al. D-2-hydroxyglutarate and L-2-hydroxyglutarate inhibit IL-12 secretion by human monocyte-derived dendritic cells. *Int J Mol Sci.* 2019;**20**(3):742.
 - 71 Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. *Cancer Res.* 2011;**71**(17):5697–706.
 - 72 Kieper WC, Prlic M, Schmidt CS, Mescher MF, Jameson SC. IL-12 enhances CD8 T cell homeostatic expansion. *J Immunol.* 2001;**166**(9):5515–21.
 - 73 Biscari L, Kaufman CD, Farré C, Huhn V, Pacini MF, Balbi CB, et al. Immunization with lipopolysaccharide-activated dendritic cells generates a specific CD8(+) T cell response that confers partial protection against infection with *Trypanosoma cruzi*. *Front Cell Infect Microbiol.* 2022;**12**:897133.
 - 74 Friedrich M, Hahn M, Michel J, Sankowski R, Kilian M, Kehl N, et al. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma. *Neuro-Oncology.* 2023;**25**(2):263–76.
 - 75 Gowda P, Patrick S, Singh A, Sheikh T, Sen E. Mutant isocitrate dehydrogenase 1 disrupts PKM2-beta-catenin-BRG1 transcriptional network-driven CD47 expression. *Mol Cell Biol.* 2018;**38**(9):e00001-18.
 - 76 Ma D, Zhan D, Fu Y, Wei S, Lal B, Wang J, et al. Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1. *Cancer Lett.* 2021;**517**:35–45.
 - 77 Wang Z, Zhang C, Liu X, Wang Z, Sun L, Li G, et al. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. *Onco Targets Ther.* 2016;**5**(11):e1196310.
 - 78 Mu L, Long Y, Yang C, Jin L, Tao H, Ge H, et al. The IDH1 mutation-induced oncometabolite, 2-hydroxyglutarate, may affect DNA methylation and expression of PD-L1 in gliomas. *Front Mol Neurosci.* 2018;**11**:82.
 - 79 Kadiyala P, Carney SV, Gauss JC, Garcia-Fabiani MB, Haase S, Alghamri MS, et al. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. *J Clin Invest.* 2021;**131**(4):e139542.
 - 80 Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. *Cell.* 2016;**164**(3):550–63.
 - 81 Rover LK, Gevensleben H, Dietrich J, Bootz F, Landsberg J, Goltz D, et al. PD-1 (PDCD1) promoter methylation is a prognostic factor in patients with diffuse lower-grade gliomas harboring Isocitrate dehydrogenase (IDH) mutations. *EBioMedicine.* 2018;**28**:97–104.
 - 82 Liu C, Zhang Z, Ping Y, Qin G, Zhang K, Maimela NR, et al. Comprehensive analysis of PD-1 gene expression, immune characteristics and prognostic significance in 1396 glioma patients. *Cancer Manag Res.* 2020;**12**:4399–410.
 - 83 Zhang J, Wang J, Marzese DM, Wang X, Yang Z, Li C, et al. B7H3 regulates differentiation and serves as a potential biomarker and theranostic target for human glioblastoma. *Lab Invest.* 2019;**99**(8):1117–29.
 - 84 Zhang M, Zhang H, Fu M, Zhang J, Zhang C, Lv Y, et al. The inhibition of B7H3 by 2-HG accumulation is associated with downregulation of VEGFA in IDH mutated gliomas. *Front Cell Dev Biol.* 2021;**9**:670145.
 - 85 Xie C, Liu D, Chen Q, Yang C, Wang B, Wu H. Soluble B7-H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4/NF-kappaB pathway. *Sci Rep.* 2016;**6**:27528.
 - 86 Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, et al. Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature. *Cancer Cell.* 2017;**31**(4):501–515 e8.

- 87 Sorensen MD, Nielsen O, Reifenger G, Kristensen BW. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status. *Brain Pathol.* 2021;**31**(3):e12921.
- 88 Ortmann CA, Eisele L, Nüchel H, Klein-Hitpass L, Führer A, Dührsen U, et al. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. *Ann Hematol.* 2008;**87**(10):809–18.
- 89 Goodyear O, Agathangelou A, Novitzky-Basso I, Siddique S, McKean T, Ryan G, et al. Induction of a CD8⁺ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. *Blood.* 2010;**116**(11):1908–18.
- 90 Zhang X, Mathews CK. Effect of DNA cytosine methylation upon deamination-induced mutagenesis in a natural target sequence in duplex DNA. *J Biol Chem.* 1994;**269**(10):7066–9.
- 91 Shen JC, Rideout WM 3rd, Jones PA. The rate of hydrolytic deamination of 5-methylcytosine in double-stranded DNA. *Nucleic Acids Res.* 1994;**22**(6):972–6.
- 92 Frederico LA, Kunkel TA, Shaw BR. A sensitive genetic assay for the detection of cytosine deamination: determination of rate constants and the activation energy. *Biochemistry.* 1990;**29**(10):2532–7.
- 93 Beletskii A, Bhagwat AS. Transcription-induced mutations: increase in C to T mutations in the nontranscribed strand during transcription in *Escherichia coli*. *Proc Natl Acad Sci USA.* 1996;**93**(24):13919–24.
- 94 Bello MJ, Alonso ME, Amiñoso C, Anselmo NP, Arjona D, Gonzalez-Gomez P, et al. Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. *Mutat Res.* 2004;**554**(1–2):23–32.
- 95 Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. *Oncogene.* 2008;**27**(45):5944–58.
- 96 Song H, Kim JK, Cosman D, Choi I. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. *Cell Immunol.* 2006;**239**(1):22–30.
- 97 Mameessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G, et al. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. *Cancer Res.* 2011;**71**(21):6621–32.
- 98 Baragano Raneros A, Martín-Palanco V, Fernandez AF, Rodriguez RM, Fraga MF, Lopez-Larrea C, et al. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia. *Genes Immun.* 2015;**16**(1):71–82.
- 99 Horrigan SK, Reproducibility Project: Cancer Biology. Replication study: the CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors. *elife.* 2017;**6**:e18173.
- 100 Fagerholm SC, Guenther C, Lloret Asens M, Savinko T, Uotila LM. Beta2-integrins and interacting proteins in leukocyte trafficking, immune suppression, and immunodeficiency disease. *Front Immunol.* 2019;**10**:254.
- 101 McMurry H, Fletcher L, Traer E. IDH inhibitors in AML-promise and pitfalls. *Curr Hematol Malig Rep.* 2021;**16**(2):207–17.
- 102 Dennison JL, al-Ali H, Volmar CH, Brothers S, Watts J, Wahlestedt C, et al. Functional drug screening of small molecule inhibitors of epigenetic modifiers in refractory AML patients. *Cancers (Basel).* 2022;**14**(17):4094.
- 103 Sharma N, Mallela AN, Shi DD, Tang LW, Abou-al-Shaar H, Gersey ZC, et al. Isocitrate dehydrogenase mutations in gliomas: a review of current understanding and trials. *Neurooncol Adv.* 2023;**5**(1):vdad053.
- 104 Unruh D, Zewde M, Buss A, Drumm MR, Tran AN, Scholtens DM, et al. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers. *Sci Rep.* 2019;**9**(1):8946.
- 105 Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opaalenik SR, Li H, et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. *Nat Commun.* 2018;**9**(1):248.
- 106 Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, et al. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. *Oncotarget.* 2017;**8**(69):114156–72.
- 107 Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, et al. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. *Sci Rep.* 2019;**9**(1):6136.
- 108 Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J, et al. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor belinostat in a murine hepatocellular carcinoma model. *Cancer Immunol Immunother.* 2019;**68**(3):379–93.
- 109 Platten M, Bunse L, Wick A, Bunse T, le Cornet L, Harting I, et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. *Nature.* 2021;**592**(7854):463–8.